TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of rectal adenocarcinoma~* tumors located within 10 cm from the anal verge by rigid proctoscopy measurement~* Complete clinical response after neoadjuvant treatment with chemoradiotherapy for rectal tumors clinical and radiologically staged as T3-4 N0 M0 or T (any) N + M0~* Absence of colorectal synchronous tumors~* Age between 18 and 75 years~* ECOG performance scale ≤ 2,~* last dose of chemotherapy / radiation therapy in up to 12 weeks~* Good organic function~* Absence of serious comorbidities defined by the doctor to prevent surgical resection of the rectum and / or neoadjuvant therapy.~Exclusion Criteria:~* Comorbidities clinically significant where surgical resection and / or neoadjuvant therapy is impossible, according to medical assessment.~* Prior antineoplastic therapy different from neoadjuvant therapy.~* History of Crohn's disease or ulcerative colitis.~* Confirmation or strongly suspected inherited polyp syndrome.~* Pregnant women or during lactation (women of childbearing age should have a negative pregnancy test).~* Concurrent participation in another research protocol involving therapeutic intervention.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rectal resection (Type: ACTIVE_COMPARATOR): Surgical rectal resection
- Observation (Type: EXPERIMENTAL): Conservative approach

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Emergency Egress and Information System for Persons With Vision Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must Be Blind with no better vision than light perception~* Must be able to walk the necessary distances, i.e., three hours of intermittent indoor walking~* OMCT (Orientation-Memory Concentration Test) of 10 or less~Exclusion Criteria:~* Patients currently being treated at Atlanta VA Medical Center

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Egress Badge Performance (Type: EXPERIMENTAL): Blind subjects are walked into a building to a specific location, and then are asked to find their way out of the building.
- Baseline Egress Performance (Type: NO_INTERVENTION): Blind subjects are walked into a building to a particular location and then asked to find their way out of the building.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: PK of Piperacillin/Tazobactam in Adults Undergoing ECMO

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age or older~* Initiated on VV ECMO for acute respiratory distress syndrome~* Receiving piperacillin/tazobactam~Exclusion Criteria:~* Pregnancy~* Massive blood transfusion (10 units or more of of PRBC) within a 24-hour period~* Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VV ECMO (Type: None): Patients 18 years of age or older, initiated on veno-venous (VV) ECMO for acute respiratory distress syndrome, and receiving piperacillin/tazobactam.Four blood samples will be obtained after the first dose of piperacillin/tazobactam: one sample before the second dose, 30-minutes, 2-hours, and 6-hours into the infusion. An additional four blood samples will be drawn on day 2 at the same time points.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Smart Glucose Meter Project

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* Diagnosis of Diabetes Mellitus (Type 1 or Type 2)~* Currently, non-compliant with prescribed glucose testing regimen~* HbA1c of 7.5 or greater within the last six months~Exclusion Criteria:~* Actively being treated for substance abuse~* Treatment for a thought disorder within the past year~* Non-English speaking~* Persons who are legally blind~* Women who are pregnant~* Cognitively or decisionally impaired as determined by practitioner~* Persons using an insulin pump

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
- Intervention (Type: ACTIVE_COMPARATOR): Home diabetes monitoring by patient using cellular enabled glucometer to communicate information and receive feedback.~Care provider can access raw and analyzed patient data; Physician receives report summary.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pediatric subjects with severe forms of sickle cell anemia (HbSS, HbSβ0 thalassemia, HbSD, HbSOArab)~2. Age: ≥ 2 and \< 11 years of age, at the time of enrollment~3. Conditional TCD Velocity (170 - 199cm/sec) by Transcranial Doppler ultrasonography examination within 3 months of enrollment~4. Parent or guardian willing and able to provide informed consent~5. Ability to comply with study related treatments, evaluations, and follow-up~Exclusion Criteria:~1. Prior abnormal TCD Velocity~2. History of clinical stroke~3. Inability to take or tolerate daily oral hydroxyurea, including~   * Known allergy to hydroxyurea therapy~  * Known positive serology to HIV infection~  * Known malignancy~  * Current lactation~4. Abnormal laboratory values at initial evaluation (temporary exclusions):~   * Hemoglobin concentration \< 6.0 gm/dL~  * Absolute reticulocyte count \< 100 x 10\^9/L with a hemoglobin concentration \< 8.0 gm/dL~  * WBC count \< 3.0 x 10\^9/L~  * Absolute neutrophil count (ANC) \< 1.0 x 10\^9/L~  * Platelet count \< 100 x 10\^9/L~5. Current use of therapeutic agents for sickle cell disease (e.g., hydroxyurea, arginine, decitabine, magnesium, chronic transfusions). Subjects must be off therapeutic agents for sickle cell disease for at least 3 months prior to enrollment.~6. Current participation in other therapeutic clinical trials~7. Serum creatinine more than twice the upper limit for age OR ≥ 1.0 mg/dL~8. Any condition or chronic illness, which in the opinion of the clinical investigator makes participation ill-advised~9. Pregnancy (for post-menarchal females only)~10. Erythrocyte transfusion within the past 2 months~11. Previous stem cell transplant or other myelosuppressive therapy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Standard Therapy: Observation (Type: NO_INTERVENTION): Half of the subjects will be randomized to clinical observation only, which includes monthly visits with clinical evaluations, laboratory tests, and TCD endpoint examinations
- Hydroxyurea (Type: EXPERIMENTAL): Half of the subjects will be randomized to hydroxyurea, taken as capsules (300 mg, 400 mg, or 500 mg), or as a liquid formulation (100 mg/mL). Hydroxyurea will be administered once daily by mouth. Subjects will be monitored monthly with clinical evaluations, laboratory tests, and TCD endpoint examinations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of a Sub-Conjunctival Insert

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Be of legal age~* Insulin dependent diabetes requiring daily finger pricking to monitor blood glucose~* Sign written Informed Consent~Exclusion Criteria:~* Inability to follow the protocol schedule~* Participating in another clinical study~* Pregnant or lactating females~* Any ongoing condition that would prevent from proper handling of the instrument (e.g. blindness, strong impaired vision, impaired motor skills)~* Any known hypersensitivity to any of the products to be used in the study, including preservatives etc.~* Malignancies requiring therapy during the study~* Severe chronic diseases e.g. renal failure, liver cirrhosis etc. which may interfere with the conduct or completion of the study~* Poorly controlled diabetes mellitus with prior hemoglobin A1C greater than 10%~* Any ocular disease requiring topical medication besides those permitted by this protocol.~* Ocular or other condition which increase the risk of ocular surgery, e.g. acute or chronic conjunctivitis or blepharitis, corneal disorders, previous eye surgery or eye surgery within the following 12 weeks, coagulation disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: ACTIVE_COMPARATOR): In the Cohort 1 an uncoated Insert and the photometer version 1 is used. Twelve trial subjects are appointed into 4 subgroups. The difference between these subgroups is the wearing time of the insert.
- Cohort 2 (Type: ACTIVE_COMPARATOR): Cohort 2 consists of 12 trial subjects who are appointed to 2 subgroups. One group will wear the insert for a minimum of 12 month and the other group for a minimum duration of 18 month. In Cohort 2 an improved insert is used. The photometer will be the same than in cohort 1.
- Cohort 3 (Type: ACTIVE_COMPARATOR): Cohort 3 only differs in the used photometer from cohort 2.
- Cohort 4 (Type: ACTIVE_COMPARATOR): Twelve trial subjects are appointed to two subgroups that differ in the minimum wearing duration of the insert (12 month and 18 month). In Cohort 4 a new insert will be tested together with a better photometer.
- Cohort 5 (Type: ACTIVE_COMPARATOR): The difference between Cohort 5 and Cohort 4 is that the best tested insert and the best evaluated photometer will be used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18-85 years old.~2. Patients with chronic lower extremity wounds (including thermal) that are greater than 3 months, but less than 12 months old.~3. Patients with full thickness wounds.~4. Patients with at least one wound that is ≥5 cm2 and\<75 cm2 in size.~5. Patient who is able to complete required site study visits and procedures in good faith~Exclusion Criteria:~1. Patients admitted to the hospital at the time of enrollment.~2. Patients who are pregnant, nursing or plan to become pregnant while participating in the study. If of child-bearing potential, unwillingness to use effective birth control while participating in the study.~3. Suspicion of or diagnosis of osteomyelitis underlying the wound.~4. Patients who have received an investigational agent or intervention within the prior 30 days or plan to use within the study period.~5. Patient with sinus tracts, enterocutaneous fistulas or other epithelialized tracts.~6. Patients who require skin grafting.~7. Patients diagnosed with a highly disruptive, non-controlled mental health disorder (e.g.., bipolar, or schizophrenia.~8. Patients with a history of prior drug abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Amniotic Fluid Injection (Type: EXPERIMENTAL): Processed Amniotic Fluid. Dose is 1ml/5cm2; Route: injected directly into wound; Limited to two injections. The wound will then be dressed according to standard of care.
- Standard of Care Wound Treatment Regimen (Type: ACTIVE_COMPARATOR): Primary dressings are variable and based on the moisture content and microorganism load. In general, wounds respond differently to various topical treatments. Through our clinical practice, we have found that wounds plateau with the same topical for greater than 4 weeks, hence changing antimicrobial topical helps to manage the bacterial overgrowth. We will start with our application of our slurry, a 1:1:1 ratio of Nystatin ointment, Mupirocin Ointment, and Bacitracin Ointment. This slurry will be applied directly to the cleansed wound, followed by silver gauze/foam product to all wounds. Types of silver product- site and comfort predict use of Restore, Mepilex-AG, or Mepitel-AG. If allergies to the above slurry occurs, we will use medical honey with or without bacitracin. If ointment related rash present with transition to silver product only or silver product plus medical honey.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: FastFrame Knee Spanning and Damage Control Kit PMCF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be 18 years of age or older~* Patient must be treated with either the Knee Spanning or Damage Control FastFrame External Fixation System according to the European Economic Area (EEA) indications\*~EEA Indications (a subset of the cleared US indications):~The FastFrame External Fixation System - Knee Spanning Kit is indicated for use in treatment of long bone (distal femur, proximal tibia) fractures. Specifically, the system is intended for temporary stabilization of open or closed fractures about the knee, typically in the context of polytrauma or where open or alternative closed treatment is undesirable or otherwise contraindicated.~The FastFrame External Fixation System - Damage Control Kit is indicated for use in treatment of mid-shaft long bone (femur, tibia) fractures. Specifically, the system is intended for temporary stabilization of open or closed fractures of the femur and tibia, typically in the context of polytrauma or where open or alternative closed treatment is undesirable or otherwise contraindicated.~Exclusion Criteria:~* Patient has an active or suspected infection~* Patient has conditions that limit their ability and/or willingness to follow instructions during the healing process~* Patient has inadequate skin, bone, or neurovascular status~* Patient is a prisoner~* Patient is pregnant and/or breastfeeding~* Patient is a known current alcohol and/or drug abuser in the opinion of the Investigator~* Patient has a mental or neurologic condition that will not allow for proper Informed Consent and/or participation in follow-up program in the opinion of the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FastFrame External Fixation System - Knee Spanning or Damage Control Kit (Type: EXPERIMENTAL): The patient must have been treated with either Knee Spanning or Damage Control FastFrame External Fixation System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical unequivocal diagnosis of Alopecia Areata (patchy, univeralis and totalis), on both scalp and eyebrows as assessed by the investigator.~* Maximal disease duration of current episode of Alopecia Areata on the eyebrows of 3 years at screening.~* Maximal Alopecia Areata disease duration - defined as years of active disease - in other locations than eyebrows of 10 years at screening.~Exclusion Criteria:~* Clinical diagnosis of diffuse type alopecia areata as assessed by the investigator.~* Any topical, intralesional therapy or procedure applied within 2 cm of the treatment area, within 4 weeks of randomisation, which in the opinion of the investigator, could interfere with the trial assessments. This includes, but is not limited to: corticosteroids, calcineurin inhibitors, calcipotriol, minoxidil, antimicrobials, prostaglandin analogs (e.g. bimatoprost), herbal extracts, topical immunotherapy with allergens or irritants and any laser or phototherapy, and eyebrow tattoo.~* Any systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), chloroquin derivatives, corticosteroids (including intralesional treatment outside the trial treatment area), or any other systemic therapy that in the opinion of the investigator could affect hair regrowth, within 4 weeks prior to randomisation.~* Any biologic medicinal product targeting the immune system within 5 half-lives and minimum 4 weeks prior to randomisation (e.g. anti-TNFα, anti-IL17, anti IL12/23, anti IL-4Rα targeting drugs).~* Systemic JAK inhibitor Ruxolitinib (Jakafi®/Jakavi®), Tofacitinib (Xeljanz®) at any time prior to randomisation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LEO 124249 ointment 30 mg/g (Type: EXPERIMENTAL): Ointment to be applied on the eyebrow twice daily.
- LEO 124249 ointment vehicle (Type: PLACEBO_COMPARATOR): Ointment to be applied on the eyebrow twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Functional Respiratory Imaging and Orkambi in CF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of CF (homozygous for the F508del mutation must be present, this should be documented in the medical history).~* Age ≥ 12 years~* FEV1 \> 50%~* Signed informed consent. If patient is a minor, parents/guardians must give written informed consent~* Patient must be on a stable regimen of CF medication for 4 weeks prior to Visit~Exclusion Criteria:~* FEV1 \< 50%~* Anticipated requirement for hospitalization within the next three weeks~* History of pneumothorax within the past 6 months prior to Visit 1~* History of haemoptysis requiring embolization within the past 12 months prior to Visit 1~* Unable or unwilling to complete study visits or provide follow-up data as required per the study protocol~* Has taken Intravenous (IV) antibiotics within the past 4 weeks prior to Visit 1~* Has ongoing exacerbation or Allergic bronchopulmonary aspergillosis (ABPA)~* Pregnant or lactating female~* Posttransplant patients~* Patients with severe hepatic impairment

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orkambi open-label arm (Type: EXPERIMENTAL): Open-label study: all subjects will receive Orkambi during 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues